研究局部黏附激酶抑制剂GSK2256098在复发性胶质母细胞瘤患者中的效果并评估[11C]GSK2256098的肿瘤穿透性
在I期研究的扩展队列中,13例复发性胶质母细胞瘤患者接受GSK2256098三个剂量队列(1000 mg、750 mg、500 mg,均每日两次)治疗,最大耐受剂量为1000 mg每日两次,剂量限制性毒性为脑水肿相关。8例患者参与PET子研究,[11C]GSK2256098在肿瘤组织的分布容积为0.9,周围T2增强区为0.5,正常脑为0.4。3例患者最佳疗效为疾病稳定,其中1例治疗11.3个月。
要点
- GSK2256098最大耐受剂量为1000 mg每日两次,剂量限制性毒性为脑水肿相关。
- 治疗相关不良事件(>25%)为腹泻、疲乏和恶心。
- [11C]GSK2256098在肿瘤组织分布容积0.9,高于正常脑0.4,提示肿瘤相关血脑屏障破坏。
核心结论
- GSK2256098在复发性胶质母细胞瘤患者中可耐受。
- GSK2256098以低水平穿过血脑屏障进入正常脑,但以明显更高水平进入肿瘤,与肿瘤相关血脑屏障破坏一致。
- GSK2256098的额外临床试验正在进行中。
研究设计与样本
- I期研究内的扩展队列,评估GSK2256098在复发性胶质母细胞瘤患者中的安全性、耐受性、药代动力学和临床活性。
- 患者接受GSK2256098治疗直至疾病进展或不良事件退出,共13例患者进入3个剂量队列(1000 mg、750 mg、500 mg,均每日两次)。
- 第1天采集系列药代动力学样本;第9至20天之间单日给予静脉[11C]GSK2256098微剂量,进行90分钟PET扫描并同步采集药代动力学样本。
- 每6周通过MRI评估疗效。
主要发现
- 最大耐受剂量为1000 mg每日两次,剂量限制性毒性为脑水肿相关。
- 治疗相关不良事件(>25%)为腹泻、疲乏和恶心。
- 8例患者参与PET子研究,[11C]GSK2256098分布容积估计值在肿瘤组织为0.9,周围T2增强区为0.5,正常脑为0.4。
- 3例患者最佳疗效为疾病稳定,其中1例治疗11.3个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: GSK2256098 is a novel oral focal adhesion kinase (FAK) inhibitor. Preclinical studies demonstrate growth inhibition in glioblastoma cell lines. However, rodent studies indicate limited blood-brain barrier (BBB) penetration. In this expansion cohort within a phase I study, the safety, tolerability, pharmacokinetics (PK), and clinical activity of GSK2256098 were evaluated in patients with recurrent glioblastoma. Biodistribution and kinetics of [11C]GSK2256098 were assessed in a substudy using positron-emission tomography (PET). METHODS: Patients were treated with GSK2256098 until disease progression or withdrawal due to adverse events (AEs). Serial PK samples were collected on day 1. On a single day between days 9 and 20, patients received a microdose of intravenous [11C]GSK2256098 and were scanned with PET over 90 minutes with parallel PK sample collection. Response was assessed by MRI every 6 weeks. RESULTS: Thirteen patients were treated in 3 dose cohorts (1000 mg, 750 mg, 500 mg; all dosed twice daily). The maximum tolerated dose was 1000 mg twice daily. Dose-limiting toxicities were related to cerebral edema. Treatment-related AEs (>25%) were diarrhea, fatigue, and nausea. Eight patients participated in the PET substudy, with [11C]GSK2256098 VT (volume of distribution) estimates of 0.9 in tumor tissue, 0.5 in surrounding T2 enhancing areas, and 0.4 in normal brain. Best response of stable disease was observed in 3 patients, including 1 patient on treatment for 11.3 months. CONCLUSIONS: GSK2256098 was tolerable in patients with relapsed glioblastoma. GSK2256098 crossed the BBB at low levels into normal brain, but at markedly higher levels into tumor, consistent with tumor-associated BBB disruption. Additional clinical trials of GSK2256098 are ongoing.
引用
- Brown NF, Williams M, Arkenau HT, et al. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro Oncol. 2018. PMID: 29788497. doi:10.1093/neuonc/noy078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。